Meeting at J.P. Morgan 2024?
Looking for partnering or investment with Cureteq or Oncoteq? CEO Mads Dalsgaard, CFO Swati Mehta, and CBO Sarah Holland will be attending so please reach out to set up meeting in San Francisco
Oncoteq completes another in-licensing deal, adding a potential best-in-class CD30 antibody drug conjugate from Tubulis to its oncology pipeline
OncoteqAG (Oncoteq), a clinical stage biotech company specializing in novel and innovative cancer treatments, is expanding its development pipeline by in-licensing the potential best-in-class antibody ...
Oncoteq further expands its pipeline, in-licensing a promising treatment for breast cancer
Oncoteq, a clinical stage biotech company specializing in innovative cancer treatments, today announces its second in-licensing deal as it obtains a world-wide exclusive license to a novel compound wi ...
Angelo Guainazzi joins Oncoteq as Program Lead
We are very pleased to welcome Angelo Guainazzi to the Oncoteq AG team as Global Program Leader. Angelo brings over a decade of experience in clinical drug development in mainly on ...
Cureteq’s CBO, Sarah Holland, interviewed about career, the role of CBO and Cureteq.
In the latest interview article from Sejelas, Cureteq’s Chief Business Officer, Sarah Holland, shares her career story and her take on the role of Chief Business Officer and about Cureteq.
Inessa Polyakova joins Oncoteq AG as Global Development Medical Director
We are very pleased to welcome Innessa Polyakova brings over 18 years of experience in clinical research, medical monitoring and drug development in hematology and oncology from across biotech and sma ...
Steven Mortier joins Oncoteq AG as Global Program Leader
We are pleased to inform you that Steven Mortier is joining us at Oncoteq AG, as Global Program Leader. Steven Mortier brings more than two decades of experience from clinical drug development and pro ...
Sarah Holland appointed as Chief Business Officer
Sarah Holland joins the Cureteq team as Chief Business Officer. Sarah brings over 30 years of biopharma industry experience, spanning the full value chain from R&D, Commercial and Business Develop ...
Dr. Andreas Penk joins the Board of Directors at Cureteq AG
We are very pleased to announce that Dr. Andreas Penk joins the Board of Directors at Cureteq AG. Andreas Penk, MD by education, is a former Senior Executive with Pfizer, most recently as President, P ...
Cureteq present at the ESMO Conference
Busy and informative days at Conference, ESMO – European Society for Medical Oncology – in Paris; with our sister company and strategic partner Innoplexus.Always motivating to submerge in ...
Cureteq in-licenses oncology asset from Merck KGaA
Cureteq today announces the first of what is planned to be a series of in-licensing deals as the company takes in the compound M8891 from Merck. New development path for M8891 identified with support ...